Geography axis: coverage anchored in Latin America. Pair with exactly one subject category (Pharma, Policy & Markets, Digital Health, Medical Devices or a Therapy Area). Country, company and regulator go in tags.
Afya and Yduqs signed a merger agreement on September 23, 2026, creating a combined group with R$9.4 billion in revenue and roughly 5,900 annual medical-school seats, subject to antitrust review …
Peru’s Digemid has approved South Korean regenerative medicine company L&C Bio’s Re2O, an injectable based on human skin extracellular matrix, for commercialisation; the company plans to use Peru as a …
Mexican pharmaceutical manufacturer Sanfer has invested more than $40 million to expand pharmaceutical production capacity in Colombia, targeting export markets across Latin America and the Caribbean, according to a Sanfer-supported …
Chileans spend nearly US$100 million a year on weight-loss treatment, according to La Tercera, as seven generic semaglutide applications — including Laboratorio Chile’s Selfix — await regulatory review, putting Novo …
Cristália’s Phase 1 safety trial of polilaminina for acute spinal cord trauma was scheduled to begin 24 September 2026 after authorisation from Brazil’s health regulator, Anvisa, in January — with …
Biolab, a Brazilian pharmaceutical company, has been selected by the UN-backed Medicines Patent Pool to manufacture and sell baloxavir marboxil (Xofluza), Roche’s single-dose oral influenza treatment, in Brazil under a …
Mercado Livre launched prescription medicine sales in São Paulo on 25 September 2026, including GLP-1 drugs and antibiotics, as pharmacy chain shares fell sharply and Abrafarma said it would formally …
Argentina’s ANMAT preventively halted all production and sales by Trifarma S.R.L. and Ugal Farmacéutica S.A. and prohibited all their products nationwide, citing technical director and quality control deficiencies.
Brazil’s Health Ministry has formally asked Conitec to evaluate semaglutide and liraglutide for public-system coverage, opening a process that could reshape the country’s obesity-drug market.
Mexico’s Cofepris has granted marketing authorization for lenacapavir as twice-yearly injectable pre-exposure prophylaxis against HIV, placing Mexico among a small group of countries with regulatory access to the long-acting prevention …
You must be logged in to post a comment.